Dr. Reddy’s analysts remain cautious citing lack of near-term catalysts post Q2

Out of the 40 analysts that track Dr. Reddy’s, 13 of them have a ‘Buy’ recommendation, while 16 of them have a ‘Sell’ call. The other 11 have a ‘Hold’ rating.

Leave a Reply

Your email address will not be published. Required fields are marked *